Wasting and cachexia in patients with HIV

AIDS Patient Care and STDs

Volumn 11, Issue 4, 1997, Pages 259-267

  Cianfrocca, Mary ^a   Von Roenn, Jamie H ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; DAPSONE; DIDANOSINE; DRONABINOL; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; GROWTH HORMONE; INDINAVIR; MEGESTROL ACETATE; NANDROLONE DECANOATE; NELFINAVIR; OXANDROLONE; OXYMETHOLONE; PENTAMIDINE; RIFABUTIN; RITONAVIR; SAQUINAVIR; STAVUDINE; THALIDOMIDE; ZALCITABINE; ZIDOVUDINE;

ANOREXIA; ARTICLE; CACHEXIA; CLINICAL TRIAL; EUPHORIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN TISSUE; JOINT STIFFNESS; NUTRITIONAL SUPPORT; PARESTHESIA; SOMNOLENCE; VERTIGO;

EID: 0030921650     PISSN: 08935068     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.1997.11.259     Document Type: Article

References (57)

1. Centers for Disease Control, Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(suppl 2S):3S-15S.
2. Nahlen B., Chu S., Nwanyanwu O.C., Berkelman R.L. Martinez, S.A., Rullan, J.V. HIV wasting syndrome in the United States, AIDS 1993;7:183-188.
3. Cahill GS. Starvation in man. N Engl J Med 1970;282:668-675.
4. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-1265.
5. Chandra RK. Nutrition, immunity, and infection: Present knowledge and future directions. Lancet 1983;1:688-691.
6. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-447.
7. Guenter P, Muurahainen N, Simons G, Kosok A, Cohan GR, Rudenstein R, Turner JL. Relationships among nutritional status, disease progression, and survival in HIV infection. J Acq Imm Def Syn 1993;6:1130-1138.
8. Palenicek JP, Graham NMH, He YD, Hoover DA, Oishi JS, Kingsley L, Saah AJ, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acq Imm Def Syn 1995;10:366-373.
9. Sharkey SJ, Sharkey KA, Sutherland LR, Church DL, et al. Nutritional status and food intake in human immunodeficiency virus infection. J Acq Imm Def Syn 1992;5:1091-1098.
10. Schwenck A, Burger B, Wessel D, et al. Clinical risk factors for malnutrition in HIV-1 infected patients. AIDS 1993;7:1213-1219.
11. Graham CS, Graham BG, Bartlett JA, Heald AE, Schiffman SS. Taste and smell losses in HIV infected patients. Physiology and Behavior 1995;58:(2): 287-293.
12. Laughon BE, Druckman DA, Vernon A, et al. Preva- lence of enteric pathogens in homosexual men with and without acquired immunodeficiency syndrome. Gastroenterology 1988;94:984-993.
13. Kotler DP, Reka S, Chow K, Orenstein JM. Effects of enteric parasitoses and HIV infection upon small intestinal structure and function in patients with AIDS. J Clin Gastroenterol 1993;16(1):10-15.
14. Ullrich R, Zeitz M, Heise W, L'age M, Hoffken G, Riecken EO. Small intestine structure and function in patients infected with human immunodeficiency virus (HIV); evidence for HIV-induced enteropathy. Ann Int Med 1989;111:15-21.
15. Tracey KJ, Cerami A. tumor necrosis factor: a pleiotropic cytokine and therapeutic target, Ann Rev Med 1994;45:491-503.
16. Hellerstein MK, Meydani SN, Meydani M, et al. CA: lnterleukin-1 induced anorexia in the rat. J Clin Invest 1989;84:228-235.
17. Spiegel RJ. The alpha interferons: Clinical overview. Sem Oncol 1987;14(2):1-12.
18. Lahdevipta J, Maury CPJ, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988;85:289-291.
19. Grunfeld C, Kotler DP, Shigenaga JK, Doerrler W, Tierney A, Wang J, Pierson RN, Feingold KR, Circulating interferon levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-162.
20. Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med 1988;84: 611-616.
21. Coodley GO, Loveless MO, Nelson HD, Coodley MK. Endocrine function in the HIV wasting syndrome. J Acq Imm Def Syn 1994;7:46-51.
22. Suttmann U, Ockenga J, Hoogesttraat L, Selberg O, Schedel I, Deicher H, Muller MJ, Resting energy expenditure and weight loss in human immunodeficiency virus infected patients. Metabolism 1993;42 (9):1173-1179.
23. Grunfeld C, Pang M, Shimuzu L, Shigenaga JK, Jensen P, Feingold KR. Resting energy expenditure, caloric intake, and short term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992;55:455-460.
24. Macallan DC, Noble C, Baldwin C, Jebb SA, Prentice AM, Coward WAS, Sawyer MB, McManus TJ, Griffin GE. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:83-88.
25. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE, Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993;58:417-424.
26. Dieterich DT, Kotler DP, Busch DF, Crumpacker C, DuMond C, Dearmand B, Buhles W. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a ran- domized, double-blind, placebo-controlled multicenter study, J Infec Dis 1993;167(2):278-282.
27. Winick M, Andrassy RJ, Armstrong D, Bryan MA, Chandra RK, Kotler DP, Neary CA, Norton JA, Ro- driguez K, Rosenberg IH, Weaver KE. Guidelines for nutrition support in AIDS, Nutrition 1989;5:39-46.
28. McKinley MJ, Goodman-Block J, Lesser ML, Salbe AD. Improved body weight status as a result of nutrition intervention in adult, HIV positive outpatients. J Am Diet Assoc 1994;94:1014-1017.
29. Kotler DP, Tierney AR, Ferraro R, Cuff P, Wang J, Pierson RN, Heymsfield SB. Enteral alimentation and repletion of body cell mass in malnourished patients with acquired immunodeficiency syndrome. Am J Clin Nutr 1991;53:149-154.
30. Ockenga J, Suttmann U, Selberg O, Schlesinger A, Meier PN, Gebel M, Schedel I, Deicher H, Percutaneous endoscopic gastrostomy in AIDS and control patients: Risks and outcomes. Am J Gastroent 1996;91:1817-1822.
31. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN. Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome, J Parenteral and Enteral Nutr 1990;14:454-458.
32. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-1282.
33. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992; 69:1268-1274.
34. Loprinzi CI, Ellison NM, Schald DJ, Krock JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132.
35. Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA, Megestrol acetate in patients with AIDS related cachexia. Ann Intern Med 1994; 121:393-399.
36. Oster MH, Enders SR, Samuels SJ, Cone LA, Hooten TM, Browder HP, Flynn NM. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-408.
37. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992;67:1160-1162.
38. Henry K, Rathgaber S, Sullivan C, McCabe K. Diamellitus induced by megestrol acetate in a patient with AIDS and cachexia, Ann Intern Med 16:53-54.
39. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843-845.
40. Engleson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS (letter). AIDS 1995;9(9):1107-1108.
41. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, Lefkowitz L, Plasse TF, Shepard KV. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
42. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficency virus infection. J Clin Endocrinol Meta 1993;77:956-962.
43. Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA, Breitmeyer JB, et al. Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996;125:873-882.
44. Clemmons DR, Smith-Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant human insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992;75:2334-238.
45. Lieberman SA, Butterfield GE, Harrison D, Hoffman AR. Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994;78:404-410.
46. Waters D, Danska J, Hardy K, Koster F, Qualis C, Nickell D, Nightingale S, Gesundeit N, Watson D, Schade D. Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-assodated wasting. Ann Intern Med 1996;125:865-872.
47. Wilson JD, Griffin JE. The use and misuse of androMetabolism 1980;29:1278-1295.
48. Forbes GB. The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 1985;34:571-573.
49. Rabkin JG, Rabkin R, Wagner G. Testosterone replacement therapy in HIV illness. General Hospital Psychiatry 1995;17:37-42.
50. Gold J, High HA, Li Y, Michelmore H, Bodwworth NJ, Finlayson R, Furner VL, Allen BJ, Oliver CJ. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection. AIDS 1996;10:745-752.
51. Hengge UR, Baumann M, Maleba R, Brockmeyer NH, Goos M. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection, British J Nutrition 1996;75:129-138.
52. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996;10:1657-1662.
53. Hellerstein MK, Wu K, McGrath M, Faix D, George D, Shckleton CHL, Horn W, Hoh R, Neese RA. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immunodeficiency syndrome: Relation to indices of cytokine production. J of Acq Imm Def Syn 1996;11:258-270.
54. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxi- fylline decreased TNF expression and serum triglycerides in people with AIDS. ACTG#160 Team. J Acquir Immun Defic Synd 1993a;7;787-794.
55. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1995;173:699-703.
56. Tramontane JM, Utaipat U, Molloy A, et al, Thalidomide treatment reduces TNF production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-397.
57. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, Dewar RL, Lane C, Freedman VH, Kaplan G. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M, tuberculosis infection. J Acq Imm Def Syn 1996;11:247-257.